

5 Brief description of the drawings and tables10 **Table 1**

Sequence of the primers used for genomic typing of HA-1 alleles by sequence-specific amplification.

10

**Table 2**

Sequence of the primers and probes used for genomic typing of HA-1 alleles by amplification and sequence-specific hybridization.

15 **Table 3**

Cellular and genomic typing for HA-1 in three HLA-A\*0201 positive families

**Table 4.**

Comparison of cellular and genomic typing by PCR or LiPA of HA-1 in family 1.

20

**Table 5.** (Sequence ID Nos.: 25-28)

KIAA0223 sequence polymorphism in mH HA-1 positive and HA-1 negative individuals.

Sequencing of HA-1 region in KIAA0223 gene in HA-1 +/+ and HA-1-/- homozygous

individuals and KG-1 revealed two alleles differing in two nucleotides resulting in a one

25 amino acid difference (H to R) and designated HA-1<sup>H</sup> and HA-1<sup>R</sup>. For DH and vR 6 independent PCR products were sequenced. For KG-1 8 PCR products were sequenced.

Figure 1. Reconstitution of HA-1 with HPLC fractionated peptides eluted from HLA-A2.1 molecules in a <sup>51</sup>Cr-release assay with mH HA-1 specific T cell clone 3HA15.

30 a. Peptides were eluted from 90.10° HA-1 and HLA-A2.1 positive Rp cells and separated using reverse phase HPLC with HFBA as organic modifier.

b. Fraction 24 of the first HPLC dimension that contained HA-1 activity was further fractionated by reverse phase HPLC with TFA as organic modifier.

c. HA-1 containing fraction 27 of the second gradient was further chromatographed with a 35 third shallower gradient consisting of 0.1% acetonitrile/min. Background lysis of T2 by the

5 The clone Q66.9 is specific for the influenza matrix peptide 58-66. No TNF $\alpha$  production  
was observed after transfection of the pcDNA3.1(+) vector alone (results not shown).

**Figure 4.**

a. Binding of HA-1<sup>H</sup> and HA-1<sup>R</sup> peptides to HLA-A2.1. The binding of HA-1<sup>H</sup> and HA-1<sup>R</sup>  
10 peptides were assayed for their ability to inhibit the binding of fluorescent peptide  
FLPSDCFPSV to recombinant HLA-A2.1 and  $\beta$ 2-microglobulin in a cell free peptide  
binding assay. One representative experiment is shown. The IC50 is determined on the  
results of 4 experiments and was 30 nM for VLHDDLLEA and 365 nM for VLRDDLLEA.  
b. Reconstitution assay with different concentrations of synthetic HA-1<sup>R</sup> peptide with HA-1  
15 specific T cells. The HA-1<sup>R</sup> peptide was titrated and preincubated with T2 cells. Three HA-1  
specific T cell clones, 5W38, 3HA15 and clone 15 were added and a 4 hr  $^{51}$ Cr-release assay  
was performed. Background lysis of T2 by the CTL in the absence of any peptide was for  
3HA15 4%, for clone 15 10% and for 5W38 2%. Positive control lysis was for 3HA15  
46%, for clone 15 47% and 5W38 48%.

20

**Figure 5** (Sequence ID Nos.: 17-22)

Sequences and genomic structure of the HA-1 locus. Figure 1a, coding sequences of the H and  
R alleles of HA-1. Bold characters indicate the polymorphic nucleotides. Figure 1b, exon-  
intron boundaries of the HA-1 locus. Exon sequences are shown in uppercase, intron  
25 sequences in lowercase.

**Figure 6**

Genomic typing of HA-1 alleles in clinical samples. Genomic typing was performed by  
sequence-specific amplification, by use of the two primer sets of Table 1. The two upper  
30 fragments in the gel originate from the H-allele, the two lower fragments from the R-allele.

**Figure 7**

HA-1 typing by LiPA of family 1

5 regression analysis with the prismgraph software. Synthetic peptides were manufactured on  
a Abimed 422 multiple peptide synthesizer (Abimed, Langenfeld, Germany) and were more  
than 90% pure as checked by reverse phase HPLC.

#### 1.2.6. RT-PCR amplification and sequencing of KIAA0223 region coding for HA-1

10

Total of mRNA was prepared from BLCL using the RNazol methode (Cinna/Biolex Laboratories, Houston, TX) or according to manufacturer's instructions (QuickPrep mRNA purification Kit, Pharmacia Biotech). cDNA was synthesized with 1  $\mu$ g RNA as template and with KIAA0223 based reverse primer 5'-GCTCCTGCATGACGGCTCTGTCTGCA-<sup>1</sup>  
15 3'. To amplify the HA-1 region of KIAA0223 the following primers were used: Forward primer 5'-GACGTCGTCGAGGACATCTCCCAT-<sup>2</sup> and reverse primer 5'-GAAGGCCACAGCAATCGTCTCCAGG-<sup>3</sup>.<sup>3</sup> Cycle parameters used were denaturation 95 °C, 1 min, annealing 58 °C, 1 min and extension 72 °C, 1 min (25 cycles). The PCR-products were purified using the Magic PCR-Preps DNA purification System (Promega) and  
20 direct cloned using the pMosBlue T-vector kit (Amersham LIFE SCIENCE). Six independent colonies from each individual were sequenced using the T7-sequencing kit (Pharmacia Biotech).

#### 1.2.7. HA-1 allele specific PCR amplification

25

In the case of HA-1 allele specific PCR amplification, cDNA was synthesized as described above. A PCR amplification was performed with allele specific forward primers: for the HA-1<sup>1</sup> allele primer H1: 5'-CCT-TGA-GAA-ACT-TAA-GGA-GTG-TGT-GCT-GCA-<sup>4</sup> for the HA-1<sup>2</sup> allele primer R1: 5'-CCT-TGA-GAA-ACT-TAA-GGA-GTG-TGT-GTT-  
30 GCG-3'<sup>5</sup> and for both reaction the reverse primer as described above was used. Cycle parameters used were denaturation 95 °C, 1 min, annealing 67 °C, 1 min and extension 72 °C, 1 min (25 cycles).

#### 1.2.8. Cloning and expression of HA-1<sup>1</sup> and HA-1<sup>2</sup> allelic region of KIAA0223.

<sup>1</sup> (Sequence ID No.: 30)

<sup>2</sup> (Sequence ID No.: 31)

<sup>3</sup> (Sequence ID No.: 32)

<sup>4</sup> (Sequence ID No.: 33)

<sup>5</sup> (Sequence ID No.: 34)